https://www.thebodypro.com/category/stribild-pro

Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild)

The Latest

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors Img
Neurocognitive

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
Option to Take Crushed Stribild Tablets With Food or Enteral Nutrition Img

Option to Take Crushed Stribild Tablets With Food or Enteral Nutrition

Research shows the boosted integrase inhibitor-based fixed-dose combination Stribild can be safely crushed without affecting pharmacokinetics.

By Gareth Hardy for HIV i-Base
Stribild (Elvitegravir, Cobicistat, Emtrictiabine, Tenofovir Disoproxil Fumarate) Tablet Label Revised to Expand the Patient Population Img
News

Stribild (Elvitegravir, Cobicistat, Emtrictiabine, Tenofovir Disoproxil Fumarate) Tablet Label Revised to Expand the Patient Population

Among a number of changes to Stribild's label, it has been revised to expand the patient population to include pediatric patients 12 years of age and older.

By U.S. Food and Drug Administration
Stribild in Women Img
Women

Stribild in Women

In the Waves study, Stribild was judged to be statistically superior to an atazanavir-based regimen in women.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
Integrase Inhibitors and Their Effectiveness and Safety in Women Img
Women

Integrase Inhibitors and Their Effectiveness and Safety in Women

Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
Fewer Renal or Bone Events With Atripla Than Stribild in Large Database Img
Conference Coverage

Fewer Renal or Bone Events With Atripla Than Stribild in Large Database

Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.

By Mark Mascolini
Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety Img
Conference Coverage

Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety

A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.

By Warren Tong
HIV Antiretroviral Study Highlights From IAS 2015 Img
IAS (International AIDS Society) Conference

HIV Antiretroviral Study Highlights From IAS 2015

We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.

By Myles Helfand
Stribild Safe and Effective in African Americans, 2 Studies Conclude Img
African-Americans

Stribild Safe and Effective in African Americans, 2 Studies Conclude

Stribild, compared to Atripla, was efficacious, durable, well-tolerated and safe in treatment-naive Black adults, and may be a viable switch option for virologically suppressed Black patients looking for regimen modification or simplification.

By Barbara Jungwirth
Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs Img
News

Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs

With this approval, each component of the single-tablet regimen Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) is now green-lighted for use separately in HIV treatment regimens in the U.S.

By Myles Helfand